BS_HSHN8PBB
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- age_years
- 5
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.628
- CHOLESTEROL_HOMEOSTASIS+0.536
- INTERFERON_GAMMA_RESPONSE+0.531
- MYOGENESIS+0.375
- ALLOGRAFT_REJECTION+0.361
- IL6_JAK_STAT3_SIGNALING+0.332
- NOTCH_SIGNALING+0.312
- APICAL_SURFACE+0.306
- ADIPOGENESIS+0.301
- HEDGEHOG_SIGNALING+0.283
Top 10 suppressed
- E2F_TARGETS-0.571
- G2M_CHECKPOINT-0.487
- MYC_TARGETS_V1-0.421
- PANCREAS_BETA_CELLS-0.341
- SPERMATOGENESIS-0.276
- MYC_TARGETS_V2-0.195
- ANGIOGENESIS-0.187
- MITOTIC_SPINDLE-0.183
- PROTEIN_SECRETION-0.164
- UNFOLDED_PROTEIN_RESPONSE-0.131
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_EYSS0ZDS | low-grade glioma | — | 0.923 |
| 2 | BS_WG203ECV | pilocytic astrocytoma | — | 0.892 |
| 3 | BS_0J9SHHSC | low-grade glioma | — | 0.870 |
| 4 | BS_V3REENH9 | pilocytic astrocytoma | — | 0.870 |
| 5 | BS_NB5XWMJT | low-grade glioma | — | 0.869 |
| 6 | BS_DSS3S5XD | low-grade glioma | — | 0.867 |
| 7 | BS_4Y6BCYK5 | pilocytic astrocytoma | — | 0.865 |
| 8 | BS_JH29M4KG | pilocytic astrocytoma | — | 0.862 |
| 9 | BS_EFEZB0ZH | low-grade glioma | — | 0.853 |
| 10 | BS_K2VYFVKZ | low-grade glioma | — | 0.852 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.628 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.536 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.531 | Idelalisib | — uncovered |
| MYOGENESIS | 0.375 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.361 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.332 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.312 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.306 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.301 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.283 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.276 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.258 | Inavolisib | — uncovered |
| COAGULATION | 0.251 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.245 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.239 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.228 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.202 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.197 | Inavolisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |